Killer peptide helps eliminate resistant cancer cells
Scientists have identified a Par-4 amino-terminal fragment that is released by diverse therapy-sensitive cancer cells...
List view / Grid view
Scientists have identified a Par-4 amino-terminal fragment that is released by diverse therapy-sensitive cancer cells...
Finnish researchers have found that an accumulation of gene mutations, similar to those typically seen in the development of cancer, also occur in some patients with rheumatoid arthritis.
A new study has identified how exposure to sunlight alleviates symptoms of eczema by triggering the release of a compound in the skin that dampens inflammation.
Patients who have aggressive prostate cancer could be identified by a highly accurate and simple blood test, according to a new study.
The new study suggests that defects in Tregs could be responsible for alopecia areata, a common autoimmune disorder that causes hair loss, and could potentially play a role in other forms of baldness, including male pattern baldness
The science behind harnessing the immune system to fight cancer is complicated, but a University of Rochester Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumours.
Viruses are notorious for taking over their host's operations and using them to their own advantage. But few human viruses make themselves quite as cozy as the Epstein-Barr virus, which can be found in an estimated 9/10 humans without causing any ill effects. That is, until this virus causes mononucleosis…
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Cell Medica has expanded its partnership with Baylor College of Medicine to develop an off-the-shelf allogeneic cell therapy, using T (NKT) cells...
21 June 2016 | By Victoria White, Digital Content Producer
A Penn Medicine preclinical study shows how an antibody - carbohydrate combination CAR T cell therapy could apply to range of cancer types...
16 June 2016 | By Victoria White, Digital Content Producer
Salk Institute researchers have imaged how vital receptors on the surface of T cells bundle together when activated using super-resolution microscopy...
2 June 2016 | By Victoria White, Digital Content Producer
The new collaboration builds on an earlier agreement with LUMC that gave Bellicum worldwide rights to TCR product candidates targeting solid tumours...
25 April 2016 | By Victoria White, Digital Content Producer
Researchers at the University of Dundee have made new discoveries about the importance of nutrients for a subpopulation of T-cells...